Cross Interaction between M2 Muscarinic Receptor and Notch1/EGFR Pathway in Human Glioblastoma Cancer Stem Cells: Effects on Cell Cycle Progression and Survival.
Brain Neoplasms
/ genetics
Cell Cycle
/ physiology
Cell Division
/ physiology
Cell Line, Tumor
Cell Proliferation
/ physiology
ErbB Receptors
/ metabolism
Glioblastoma
/ genetics
Humans
Neoplastic Stem Cells
/ pathology
Receptor, Muscarinic M2
/ genetics
Receptor, Notch1
/ metabolism
Signal Transduction
/ drug effects
EGFR
M2 muscarinic receptors
Notch
apoptosis
cancer stem cells
cell cycle
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
09 03 2020
09 03 2020
Historique:
received:
31
12
2019
revised:
03
03
2020
accepted:
05
03
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
17
3
2021
Statut:
epublish
Résumé
Glioblastomas (GBM) are the most aggressive form of primary brain tumors in humans. A key feature of malignant gliomas is their cellular heterogeneity. In particular, the presence of an undifferentiated cell population of defined Glioblastoma Stem cells (GSCs) was reported. Increased expression of anti-apoptotic and chemo-resistance genes in GCSs subpopulation favors their high resistance to a broad spectrum of drugs. Our previous studies showed the ability of M2 muscarinic receptors to negatively modulate the cell growth in GBM cell lines and in the GSCs. The aim of this study was to better characterize the inhibitory effects of M2 receptors on cell proliferation and survival in GSCs and investigate the molecular mechanisms underlying the M2-mediated cell proliferation arrest and decreased survival. Moreover, we also evaluated the ability of M2 receptors to interfere with Notch1 and EGFR pathways, whose activation promotes GSCs proliferation. Our data demonstrate that M2 receptors activation impairs cell cycle progression and survival in the primary GSC lines analyzed (GB7 and GB8). Moreover, we also demonstrated the ability of M2 receptor to inhibit Notch1 and EGFR expression, highlighting a molecular interaction between M2 receptor and the Notch-1/EGFR pathways also in GSCs.
Identifiants
pubmed: 32182759
pii: cells9030657
doi: 10.3390/cells9030657
pmc: PMC7140674
pii:
doi:
Substances chimiques
NOTCH1 protein, human
0
Receptor, Muscarinic M2
0
Receptor, Notch1
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Res. 2007 Apr 15;67(8):3936-44
pubmed: 17440109
J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
pubmed: 11895036
J Cell Mol Med. 2013 Apr;17(4):552-66
pubmed: 23490231
Recent Pat CNS Drug Discov. 2014;9(2):85-100
pubmed: 25413004
Cancer Res. 1997 May 1;57(9):1722-30
pubmed: 9135015
Prostate. 1997 Feb 15;30(3):160-6
pubmed: 9122040
Semin Oncol. 2011 Dec;38 Suppl 4:S2-10
pubmed: 22078644
Exp Cell Res. 2003 Mar 10;284(1):31-53
pubmed: 12648464
Cancer Invest. 2012 Jan;30(1):48-56
pubmed: 22236189
Can J Physiol Pharmacol. 2012 Aug;90(8):1145-9
pubmed: 22646904
Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31
pubmed: 8052651
Prog Med Chem. 2005;43:105-36
pubmed: 15850824
PLoS One. 2012;7(6):e38486
pubmed: 22701651
Int Immunopharmacol. 2015 Nov;29(1):105-9
pubmed: 26033491
Recent Pat CNS Drug Discov. 2008 Jun;3(2):94-103
pubmed: 18537768
Neuroradiol J. 2014 Apr;27(2):169-74
pubmed: 24750704
Cell Cycle. 2010 Mar 15;9(6):1031-6
pubmed: 20190569
Gynecol Oncol. 2002 Apr;85(1):159-64
pubmed: 11925137
Cytometry. 1992;13(8):795-808
pubmed: 1333943
Nat Rev Cancer. 2006 Jun;6(6):425-36
pubmed: 16723989
Cancer Res. 2005 Mar 15;65(6):2353-63
pubmed: 15781650
Cancer Biol Ther. 2014;15(11):1489-98
pubmed: 25482946
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Neurol Res Int. 2012;2012:878425
pubmed: 22530127
Eur J Pharmacol. 1996 Feb 22;297(3):265-73
pubmed: 8666059
Neurochem Int. 2018 Sep;118:52-60
pubmed: 29702145
Life Sci. 2012 Nov 27;91(21-22):1134-7
pubmed: 22575825
Int J Mol Sci. 2018 May 31;19(6):
pubmed: 29857516
Clin Cancer Res. 2017 Nov 15;23(22):6846-6855
pubmed: 28855349
Neurochem Int. 2015 Nov;90:261-70
pubmed: 26455407
Cent Nerv Syst Agents Med Chem. 2017;17(2):100-108
pubmed: 27488345